Relma-cel ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05765006 (ClinicalTrials.gov) | February 24, 2023 | 6/2/2023 | CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus | A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Biological: Relma-cel | Shanghai Ming Ju Biotechnology Co., Ltd. | NULL | Recruiting | 18 Years | 70 Years | All | 24 | Phase 1 | China |